A potential new class of anti-cancer drugs inhibits two or more molecular targets at once, maximizing therapeutic efficiency and safety, report scientists.
A potential new class of anti-cancer drugs inhibits two or more molecular targets at once, maximizing therapeutic efficiency and safety, report scientists.